ArticleTranslational lung cancer research2026
Impact of baseline brain metastases on survival and CNS progression in NSCLC patients treated with immune checkpoint inhibitors in real-world studies: a systematic review and meta-analysis.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain metastases (BMs) are common in non-small cell lung cancer (NSCLC) and are associated with poor prognosis. Immune checkpoint inhibitors (ICIs) have improved survival outcomes in NSCLC, but their impact on intracranial progression (IP) and survival, particularly in patients with or without baseline BMs, remains unclear. The objective of this study is to determine whether baseline BM status in patients with NSCLC BMs treated with ICIs impacts IP and survival outcomes. Methods: A systematic review and meta-analysis were conducted on observational studies published from 2015-2025 across PubMed, Embase, and Cochrane. Studies included NSCLC patients treated with ICIs, stratified by baseline BM status. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (ORs) for IP, were extracted and pooled using random-effects models. Heterogeneity and risk of bias were assessed. Results: Of 2,679 screened studies, 12 met the inclusion criteria. Among real-world studies (RWs) (n=12), HRs for OS and PFS were extracted from 10 studies. Pooled analysis showed a modest but significant increase in the hazard of death and PFS for BM+ Conclusions: ICIs appear effective regardless of BM status; however, pooled RWs suggest modestly better survival outcomes in patients without baseline BMs. Additionally, these patients may be at a lower risk for IP. Prospective studies are needed to validate these findings and guide future BM prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.